Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: iadeluca l. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. Lancet Respir Med. 2023. PMID: 36535300 Clinical Trial.
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC.
Wu YL, Lu S, Yang JC, Zhou J, Seto T, Ahn MJ, Su WC, Yamamoto N, Kim DW, Paolini J, Usari T, Iadeluca L, Wilner KD, Goto K. Wu YL, et al. Among authors: iadeluca l. JTO Clin Res Rep. 2022 Sep 9;3(10):100406. doi: 10.1016/j.jtocrr.2022.100406. eCollection 2022 Oct. JTO Clin Res Rep. 2022. PMID: 36247019 Free PMC article.
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
Mazieres J, Iadeluca L, Shaw AT, Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Kim DW, Mok T, Reisman A, Thurm H, Polli AM, Liu G. Mazieres J, et al. Among authors: iadeluca l. Lung Cancer. 2022 Dec;174:146-156. doi: 10.1016/j.lungcan.2022.11.004. Epub 2022 Nov 7. Lung Cancer. 2022. PMID: 36410210 Free article. Clinical Trial.
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Nilsson FOL, Asanin ST, Masters ET, Iadeluca L, Almond C, Cooper M, Smith S. Nilsson FOL, et al. Among authors: iadeluca l. Pharmacoeconomics. 2021 Aug;39(8):941-952. doi: 10.1007/s40273-021-01015-8. Epub 2021 Jun 3. Pharmacoeconomics. 2021. PMID: 34080140 Free PMC article. Clinical Trial.
14 results